Mark Lowdell
Founder bij INMUNE BIO, INC.
Vermogen: 17 M $ op 29-02-2024
Profiel
Founder of 6 different companies, notably: INmune Bio, Inc., Achilles Therapeutics Plc and Kuur Therapeutics Ltd.
Mark Lowdell is an entrepreneur and currently occupies the position of Chief Scientific & Manufacturing Officer at INmune Bio, Inc. (which he founded in 2015) and Scientific Founder at Achilles Therapeutics Plc.
Dr. Lowdell is also on the board of Autolomous Ltd.
and Professor at University College London, Director-Cellular Therapy at Royal Free London NHS Foundation Trust, Director-Centre for Cell, Gene & Tissue at Royal Free Hospital Medical School and Vice President of International Society For Cell & Gene Therapy.
He received a doctorate from St Bartholomew's Hospital Medical College and a doctorate from Blizard Institute.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
INMUNE BIO, INC.
8.30% | 17-04-2023 | 1 496 383 ( 8.30% ) | 17 M $ | 29-02-2024 |
Actieve functies van Mark Lowdell
Bedrijven | Functie | Begin |
---|---|---|
INMUNE BIO, INC. | Founder | 01-09-2015 |
ACHILLES THERAPEUTICS PLC | Founder | 01-11-2020 |
University College London | Corporate Officer/Principal | 01-01-1994 |
Royal Free London NHS Foundation Trust
Royal Free London NHS Foundation Trust Hospital/Nursing ManagementHealth Services Royal Free London NHS Foundation Trust operates hospitals and clinics. The company was founded on July 1, 2014 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01-02-2009 |
Royal Free Hospital Medical School | Corporate Officer/Principal | - |
International Society For Cell & Gene Therapy | Corporate Officer/Principal | - |
Autolomous Ltd. | Founder | 01-02-2019 |
Eerdere bekende functies van Mark Lowdell
Bedrijven | Functie | Einde |
---|---|---|
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Founder | - |
Immune Ventures Ltd. | Founder | - |
░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
Opleiding van Mark Lowdell
St Bartholomew's Hospital Medical College | Doctorate Degree |
Blizard Institute | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
INMUNE BIO, INC. | Health Technology |
ACHILLES THERAPEUTICS PLC | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
Kuur Therapeutics Ltd.
Kuur Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom. | Health Technology |
Royal Free London NHS Foundation Trust
Royal Free London NHS Foundation Trust Hospital/Nursing ManagementHealth Services Royal Free London NHS Foundation Trust operates hospitals and clinics. The company was founded on July 1, 2014 and is headquartered in London, the United Kingdom. | Health Services |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Immune Ventures Ltd. | |
International Society For Cell & Gene Therapy | |
Autolomous Ltd. |